Check out this nice summary by Michelle Gabriel Mcgovern published in Bloomberg BNA’s Health Care Policy Report on Sept 2014. It covers the history of 503B legislation and recent updates from the FDA regarding cGMP and guidance on bulk substances to be used in compounded products. The full report can be viewed below from the original source.

View the full report here